市場調查報告書
商品編碼
925503

增生糖尿病視網膜病變的全球市場:成長,趨勢,預測(2020年∼2025年)

Proliferative Diabetic Retinopathy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球增生糖尿病視網膜病變市場在2020年∼2025年的預測期間內,預計將以9.4%的年複合成長率增長。糖尿病性視網膜病變是由眼血管變化引起的糖尿病併發症,如果不及時治療,會引起其他嚴重的眼部疾病,並可能導致長期失明。由於人口老齡化,糖尿病和糖尿病性視網膜病的患病率增加,先進技術的應用和微創激光技術是增生性糖尿病性視網膜病市場的主要促進因素。

本報告提供全球增生糖尿病視網膜病變市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各市場區隔和各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 糖尿病患病率增加會增加糖尿病性視網膜病變的風險
    • 先進技術和微創激光技術的可用性
  • 阻礙市場要素
    • 藥品批准期限延長
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場區隔

  • 各治療類型
    • 抗VEGF劑
    • 皮質類固醇
    • 雷射手術
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • Allergan Plc
    • Hoffmann-La Roche (Genentech)
    • Oxurion NV
    • Alimera Sciences
    • BCN Peptides
    • Glycadia Pharmaceuticals
    • Kowa Group

第7章 市場機會及未來趨勢

目錄
Product Code: 68012

The Proliferative Diabetic Retinopathy Market is expected to register a CAGR of 9.4% during the forecast period. Proliferative diabetic retinopathy is a complication of diabetes caused by changes in the blood vessels of the eye which can lead to other serious eye problems, which may cause long term vision loss if not treated. Proliferative diabetic retinopathy is the most advanced stage of diabetic retinopathy which is characterized by the growth of new vessels on the surface of the retina. Some of the signs and symptoms are progressive loss of vision, fine to severe loops of new vessels that may grow on the optic disc and these new vessels may leak and resulting in retinal edema and so on. The major risk factors for proliferative diabetic retinopathy (PDR) include the duration of diabetes, for 30-34 years of diabetes increase the risk of retinopathy by 65%, according to the reports published by the Columbia University. Hence, the rising prevalence of diabetes is directly contributing to the further increase in the prevalence of proliferative diabetic retinopathy (PDR).

According to the International Agency for the Prevention of Blindness, low- and middle-income countries account for approximately 75% of the global diabetes burden, yet many people are ill-equipped to properly identify, treat and manage this disease. Furthermore, as per the study published in the Ophthalmological Journal, estimates diabetic retinopathy affects 1 in 3 people with diabetes and by the year 2040, diabetes is projected to affect 642 million adults.

Growth in the geriatric population increases the prevalence of diabetes and diabetic retinopathy and the availability of advanced technology and minimally invasive laser technique are the key driving factors in the proliferative diabetic retinopathy market.

Key Market Trends

Anti-VEGF Agents Segment is Expected to Witness a Healthy CAGR

The recent research studies suggest that in cases of proliferative diabetic retinopathy, high levels of the vascular endothelial growth factor being detected in fibrovascular tissues of eyes of diabetic patients have prompted the use of anti-VEGF as the most effective and efficient management method. According to the International Agency for the Prevention of Blindness, by the year 2040, about 224 million (35%) people worldwide will have some form of diabetic retinopathy, in addition, 70 million (11%) people will have vision-threatening diabetic retinopathy.

Anti-VEGF agents segment holds a significant market share in the proliferative diabetic retinopathy market and is anticipated to show a similar trend over the forecast period due to effective treatment which resulted in improvements in visual acuity of patients with proliferative diabetic retinopathy when comparative to improvements observed in treatment by using corticosteroids.

Rising prevalence of diabetic retinopathy and the availability of advanced technology are the key driving factors in the Anti-VEGF agent's segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global proliferative diabetic retinopathy market due to rising prevalence of diabetes and diabetic retinopathy and availability of advanced technology and minimally invasive laser technique in this region. According to the Centers for Disease Control and Prevention, approximately 4.2 million adults had diabetic retinopathy and 655,000 had vision-threatening diabetic retinopathy. Furthermore, increasing healthcare expenditure and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Proliferative Diabetic Retinopathy Market is consolidated and consists of few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Novartis AG, Regeneron Pharmaceuticals Inc, Allergan Plc, Hoffmann-La Roche (Genentech), Oxurion NV, Alimera Sciences, BCN Peptides, Glycadia Pharmaceuticals and Kowa Group.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Diabetes Increases Risk of Diabetic Retinopathy
    • 4.2.2 Availability of Advanced Technology and Minimally Invasive Laser Technique
  • 4.3 Market Restraints
    • 4.3.1 Extended Approval Time for Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Treatment Type
    • 5.1.1 Anti-VEGF Agents
    • 5.1.2 Corticosteroids
    • 5.1.3 Laser Surgery
    • 5.1.4 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Novartis AG
    • 6.1.2 Regeneron Pharmaceuticals Inc
    • 6.1.3 Allergan Plc
    • 6.1.4 Hoffmann-La Roche (Genentech)
    • 6.1.5 Oxurion NV
    • 6.1.6 Alimera Sciences
    • 6.1.7 BCN Peptides
    • 6.1.8 Glycadia Pharmaceuticals
    • 6.1.9 Kowa Group

7 MARKET OPPORTUNITIES AND FUTURE TRENDS